Lilly(Eli) & Co(LLY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 13 at 4:55 AM ET (Korea 11/13 18:55)AI-drawn chart patterns are for reference only.
Full metrics table
| Index | S&P 500, RUI | P/E | 46.89 | EPS (ttm) | 30.44 | Insider Own | 9.87% | Shs Outstand | 941.2M | Perf Week | 4.58% |
| Market Cap | 1342.71B | Forward P/E | 28.41 | EPS next Y | 42.1% | Insider Trans | -0.02% | Shs Float | 847.9M | Perf Month | 18.08% |
| Enterprise Value | 1387.32B | PEG | 0.85 | EPS next Q | 11.19 | Inst Own | 76.89% | Short Float | 0.85% | Perf Quarter | 20.94% |
| Income | 27.58B | P/S | 15.53 | EPS this Y | 46.05% | Inst Trans | 0.08% | Short Ratio | 2.82 | Perf Half Y | 41.78% |
| Sales | 86.46B | P/B | 33.36 | EPS next 5Y | 33.41% | ROA | 20.97% | Short Interest | 7.21M | Perf YTD | 32.81% |
| Book/sh | 42.79 | P/C | 274.86 | EPS past 3/5Y | 49.25% 27.59% | ROE | 86.09% | 52W High | -1.77% ($1453.00) | Perf Year | 40.23% |
| Cash/sh | 5.19 | P/FCF | 68.29 | Sales past 3/5Y | 31.69% 21.58% | ROIC | 31.61% | 52W Low | 67.81% ($850.51) | Perf 3Y | 138.79% |
| Dividend Est. | $6.82 (0.48%) | EV/EBITDA | 29.84 | EPS Y/Y TTM | 50.48% | Gross Margin | 83.63% | Volatility(W/M) | 2.85% 3.14% | Perf 5Y | 449.69% |
| Dividend TTM | 6.69 | EV/Sales | 16.05 | Sales Y/Y TTM | 45.51% | Oper. Margin | 51.25% | ATR (14) | 45.42 | Perf 10Y | 1737.62% |
| Dividend Ex-Date | 2026/11/13 | Quick Ratio | 1 | EPS Q/Q | 16.25% | Profit Margin | 31.9% | RSI (14) | 67.96 | Recom | 1.48 |
| Dividend Gr. 3/5Y | 15.24% 15.18% | Current Ratio | 1.39 | Sales Q/Q | 38.61% | SMA20 | 5.97% ($1346.87) | Beta | 0.39 | Target Price | $1501.06 |
| Payout | 26.14% | Debt/Eq | 1.23 | Earnings | 2026/10/29 | SMA50 | 15.53% ($1235.42) | Rel Volume | 0.94 | Prev Close | $1437.29 |
| Employees | 50000 | LT Debt/Eq | 1.17 | EPS/Sales Surpr. | 30.99% 8.03% | SMA200 | 28.91% ($1107.19) | Avg Volume(3M) | 2.56M | Price | $1427.28 |
| IPO | 1970/7/9 | Option/Short | Yes/Yes | Trades | 99641 | Volume | 2,412,318 | Change | -0.7% |
💊 A global large-cap pharmaceutical company with strong positions in diabetes and obesity treatments, as well as oncology, immunology, and neuroscience. Founded in 1876 by Eli Lilly in Indianapolis, Indiana, the company has been a historic pioneer in the commercialization of insulin, and more recently its revenue growth engine has expanded significantly with its obesity and diabetes therapy franchise.
Over the past 1 year, on the higher side
2% below its 1-year high.
Traded about as much as usual. That is 94% of its average volume.
Ex-dividend date: November 13
That is today. Buy before this date to receive the dividend.
LLY makes money exceptionally well
Of every $100 in sales, $51.25 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +46.0% this year.
Tap to view numbers
However, it looks expensive
For a company expected to earn $100 next year, you would pay $2,841. Peers typically go for $1,582. Compared with its own 5-year average, it is 12% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +449.7%. The S&P 500 did +62% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 0.48% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 76.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IHE iShares U.S. Pharmaceuticals ETF 0.22% 
MEDI Harbor Health Care ETF 0.21% 
PPH VanEck Pharmaceutical ETF 0.20% 
MEDX Horizon Kinetics Medical ETF 0.18% 
TMED T. Rowe Price Health Care ETF 0.17% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
LLYX Defiance Daily Target 2X Long LLY ETF 44M 
ELIL Direxion Daily LLY Bull 2X ETF 25M It is the largest in the industry
Based on market cap of $1.3T.
LLY#1 Lilly(Eli) & Co $1.3T PER 46.9 
JNJ#2 Johnson & Johnson $683B PER 43.0 
ABBV#3 Abbvie Inc $520B PER 50.7 
MRK#4 Merck & Co Inc $362B PER 150.1 
NVS#5 Novartis AG ADR $293B PER 30.6 
Earnings Analysis · 8/5 Eli Lilly ($LLY) Q2 2026 Earnings Analysis — Revenue and Adjusted EPS Significantly Beat Estimates; Full-Year Revenue Guidance Raised Investing Guides · 4/11 The Complete 2026 Guide to U.S. Dividend Aristocrats Investing Guides · 4/1 US Stock Taxes Complete Guide 2026 — Calculation Methods and Tax-Saving Strategies for Beginners See all posts on this stock FAQ
What kind of company is LLY?
LLY belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of LLY?
The market cap of LLY is approximately $1.34T, ranking 12 within its sector.
Does LLY pay dividends?
LLY has a dividend yield of approximately 0.48%, with an annual dividend of $6.82.
What is the P/E ratio of LLY?
LLY has a P/E ratio of approximately 46.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for LLY?
LLY has recorded a 52-week high of $1453.00 and a low of $850.51.
